Retrospective cohort study evaluates romiplostim’s effects on chemotherapy-induced thrombocytopenia in pediatric patients, highlighting safety and need for further efficacy research.
Romiplostim for chemotherapy‐induced thrombocytopenia (CIT) is not well‐studied in children. This single‐center retrospective cohort study describes 24 pediatric patients with solid tumors who initiated romiplostim a median of 5 months into chemotherapy (range: 0–14 months) at a median maximum dose of 6.5 µg/kg (range: 1–10). A minority of patients achieved a decrease in cycle delays (30%) or dose reductions (13%). A comparative cohort, which did not receive romiplostim, had no difference in cycle delays ( p = 0.42) or dose reductions ( p > 0.99). There were no adverse events. Romiplostim was safe in children with solid tumors, but requires further prospective study of efficacy.
No takes yet. Share an insight, caveat, or question.
Gorfinkel et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: